Novo Nordisk’s Nanexa Deal Targets Longer-Acting Obesity and Diabetes Injections

Novo Nordisk’s agreement with Swedish drug-delivery company Nanexa is a bet on making injectable obesity and diabetes medicines last longer. Announced on September 24, 2026, the exclusive global license gives Novo access to PharmaShell for up to five development programs, with monthly and quarterly dosing as target profiles. Neither dosing schedule is an established result of the partnership. 13

What the agreement covers—and what it could pay

The license applies to Nanexa’s PharmaShell platform for certain therapeutic peptide drugs targeting obesity, type 2 diabetes and other cardiometabolic diseases. Novo will lead global development and commercialization. 1331

Nanexa could receive up to €1.165 billion (approximately $1.33 billion), but that figure is a potential total, not an upfront payment. Reported terms allocate up to €615 million to upfront consideration plus development and regulatory milestones, and €550 million to sales milestones. Nanexa is also eligible for low single-digit royalties on future product sales. The sources provided do not establish how much of the €615 million is payable immediately. 143411

How PharmaShell is meant to extend drug release

PharmaShell uses atomic layer deposition to apply an ultra-thin inorganic coating to individual drug particles. The coating is designed to control and sustain release after injection. One account describes the coated particles forming a depot at the injection site, with drug released as the coating dissolves. The available sources do not establish a precise release rate or show that a particular formulation will reliably last one or three months in patients. 1363

Nanexa has reported preclinical findings for a monthly semaglutide formulation, including a smoother drug-concentration profile. Those findings are an early signal, not evidence of improved side effects, adherence or clinical outcomes in people. 48

Why the deal matters

For Novo, access to as many as five programs creates several chances to develop less-frequently administered peptide medicines rather than placing the entire effort on one formulation. For patients, a successful monthly or quarterly injection could mean fewer shots. Both are possibilities, contingent on clinical results—not benefits demonstrated by the license itself. 138

The pursuit of longer-acting treatments extends beyond this agreement: Camurus has reported Phase 1b results for a monthly semaglutide formulation, while Pfizer lists a study of a monthly weight-management candidate. Those programs provide competitive context, but the sources here do not establish how they compare with any eventual PharmaShell-based medicine. 4145

Nanexa’s shares more than doubled in early trading on September 25 after the agreement was announced following the prior day’s market close. That reaction reflects investor enthusiasm, not a forecast that Nanexa will earn the full milestone package. The decisive question now is whether Novo can turn controlled release into durable efficacy and acceptable tolerability with fewer injections. 113